Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  • Toledano, Ignasi
  • Supek, Fran
  • Lehner, Ben
Premature termination codons (PTCs) cause ~10-20% of inherited diseases and are a major mechanism of tumor suppressor gene inactivation in cancer. A general strategy to alleviate the effects of PTCs would be to promote translational readthrough. Nonsense suppression by small molecules has proven effective in diverse disease models, but translation into the clinic is hampered by ineffective readthrough of many PTCs. Here we directly tackle the challenge of defining drug efficacy by quantifying the readthrough of ~5,800 human pathogenic stop codons by eight drugs. We find that different drugs promote the readthrough of complementary subsets of PTCs defined by local sequence context. This allows us to build interpretable models that accurately predict drug-induced readthrough genome-wide, and we validate these models by quantifying endogenous stop codon readthrough. Accurate readthrough quantification and prediction will empower clinical trial design and the development of personalized nonsense suppression therapies., Work in the Supek laboratory was supported by an ERC StG ‘HYPER-INSIGHT’ (757700) and ERC CoG ‘STRUCTOMATIC’ (101088342), Horizon2020 project ‘DECIDER’ (965193), Horizon Europe project ‘LUCIA’ (101096473), Spanish government project ‘REPAIRSCAPE’, CaixaResearch project ‘POTENT-IMMUNO’ (HR22-00402), an ICREA professorship to F.S., the SGR funding from the Catalan government and a Novo Nordisk Fonden starting package. Work in the Lehner laboratory was funded by European Research Council (ERC) Advanced (grant 883742) and Consolidator (grant 616434), the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Center of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322) and the CERCA Program/Generalitat de Catalunya. The authors would like to thank the four members E. Ramírez, A. Bote, E. Julià and Ò. Fornàs of the Flow Cytometry CRG Core Unit for their support and time, together with G. Palou (IRB) for his help in retrieving the transcript sequences from the Ensembl database and all members of the Supek and Lehner laboratories for helpful discussions and suggestions.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Capítulo o parte de un libro (BookPart)

Survival Stacking Ensemble Model for Lung Cancer Risk Prediction

  • Alonso, Eduardo
  • Calle, Xabier
  • Gurrutxaga Goikoetxea, Ibai
  • Beristain Iraola, Andoni
The most well-established risk factor for lung cancer (LC) is smoking, responsible for approximately 85% of cases. The Lung Cancer Risk Assessment Tool (LCRAT) is a key advancement in this field, which predicts individual risk based on factors like smoking habits, demographic details, personal and family medical history, and environmental exposures. This paper proposes a model with fewer features that improves state of the art performance, using a simplified stacking ensemble, making it more accessible and easier to implement in routine healthcare practice. The data used in this work were derived from two cohorts in the United States: The National Lung Screening Trial (NLST) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Both our model and LCRAT achieve an AUC of 0.799 and 0.782 on test respectively. In terms of percentage of positives, in the 50% of the population, both detect 0.766 and 0.754 of the cases. The ensemble of different survival models enhances robustness by mitigating the weakness of individual models and directly impacts the efficiency of the model, increasing the efficiency and generalizability., This work has been founded by the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement no 101096473. The authors also acknowledge the National Cancer Institute for granting access to the data from the National Lung Screening Trial (NLST) and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Understanding LUng Cancer risk factors and their Impact Assessment (LUCIA): protocol for multicentre observational cohort study

  • Idoyaga-Uribarrena, Jon Eneko
  • García-Echeberria, Larraitz
  • Lecumberri, Iñigo
  • Azkona, Eider
  • Jiménez, Unai
  • Sainz-Camín, Mónica
  • Núñez-Benjumea, Francisco J.
  • Luque-Romero, Luis Gabriel
  • Erns, Benoit
  • Guiot, Julien
  • Stonans, Ilmars
  • Krams, Alvils
  • Macia, Iván
  • Garin-Muga, Alba
  • Glynne Gut, Ivo
  • Gut, Marta
  • Orcajo-Lago, Janire
  • Arana-Arri, Eunate
  • LUCIA Study Group
  • TECHNION - Israel Institute of Technology (TECH-Israel)
[Introduction] Lung cancer (LC) is the leading cause of cancer-related mortality worldwide, primarily due to diagnosis at advanced stages. Although low-dose computed tomography (LDCT) screening reduces lung cancer mortality in high-risk populations, current screening programmes are largely restricted to individuals defined by age and smoking history. This approach excludes never-smokers and individuals with non-smoking-related risk factors, limiting the equity, efficiency and scalability of lung cancer screening. The LUng Cancer risk factors and their Impact Assessment (LUCIA) project aims to overcome these limitations by developing personalised lung cancer risk prediction models and evaluating novel non-invasive technologies for early detection within a risk-adapted screening strategy., [Methods and analysis] LUCIA is a multicentre, observational, longitudinal cohort study that will recruit approximately 4000 participants across four European regions: Andalusia and the Basque Country (Spain), Liège (Belgium) and Riga (Latvia). The study population includes smokers, never-smokers and reduced smokers with low-to-moderate lung cancer risk. All participants will initially enter phase 1 (wide population screening) and may transition to phase 2 (precision screening) or phase 3 (diagnosis) based on LDCT findings, results from non-invasive screening devices and artificial intelligence-based risk prediction models. Participants will be followed up for 24 months, with assessments at baseline and at 6, 12 and 24 months. Data collection includes sociodemographic characteristics, medical history, environmental and occupational exposures, lifestyle factors, spirometry, multi-omics profiles and outputs from novel non-invasive devices, including a breath analyser, spectrometry-on-card and a skin-applied volatile organic compound sensing patch. The study will develop and validate integrated lung cancer risk prediction models and evaluate the diagnostic performance of these technologies to support population stratification and personalised screening., [Ethics and dissemination] The study will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and applicable national and European regulations. Ethical approval has been obtained from the relevant ethics committees in all participating countries. Written informed consent will be obtained from all participants. Study findings will be disseminated through peer-reviewed open-access publications, scientific conferences and communication with public health stakeholders., Funded by the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement no 101096473., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  • Toledano, Ignasi
  • Supek, Fran
  • Lehner, Ben
Premature termination codons (PTCs) cause ~10-20% of inherited diseases and are a major mechanism of tumor suppressor gene inactivation in cancer. A general strategy to alleviate the effects of PTCs would be to promote translational readthrough. Nonsense suppression by small molecules has proven effective in diverse disease models, but translation into the clinic is hampered by ineffective readthrough of many PTCs. Here we directly tackle the challenge of defining drug efficacy by quantifying the readthrough of ~5,800 human pathogenic stop codons by eight drugs. We find that different drugs promote the readthrough of complementary subsets of PTCs defined by local sequence context. This allows us to build interpretable models that accurately predict drug-induced readthrough genome-wide, and we validate these models by quantifying endogenous stop codon readthrough. Accurate readthrough quantification and prediction will empower clinical trial design and the development of personalized nonsense suppression therapies., Work in the Supek laboratory was supported by an ERC StG ‘HYPER-INSIGHT’ (757700) and ERC CoG ‘STRUCTOMATIC’ (101088342), Horizon2020 project ‘DECIDER’ (965193), Horizon Europe project ‘LUCIA’ (101096473), Spanish government project ‘REPAIRSCAPE’, CaixaResearch project ‘POTENT-IMMUNO’ (HR22-00402), an ICREA professorship to F.S., the SGR funding from the Catalan government and a Novo Nordisk Fonden starting package. Work in the Lehner laboratory was funded by European Research Council (ERC) Advanced (grant 883742) and Consolidator (grant 616434), the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Center of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322) and the CERCA Program/Generalitat de Catalunya. The authors would like to thank the four members E. Ramírez, A. Bote, E. Julià and Ò. Fornàs of the Flow Cytometry CRG Core Unit for their support and time, together with G. Palou (IRB) for his help in retrieving the transcript sequences from the Ensembl database and all members of the Supek and Lehner laboratories for helpful discussions and suggestions.